Intressa Vascular

Industry
Medical Devices
Founded Year
2017
Headquarters
Gembloux, Belgium
Employee Count
15

Key People

Assessment

Team
Aspect: First-time 10+ yrs
Summary: The leadership team comprises first-time entrepreneurs with over a decade of experience in the medical field.

While the leadership's medical expertise is valuable, their lack of previous entrepreneurial success in the MedTech sector may pose challenges in navigating the complexities of bringing a new medical device to market.

Clinical Need
Aspect: Very Strong
Summary: Aortic dissection is a life-threatening condition with significant unmet clinical needs.

Aortic dissection has high morbidity and mortality rates, and current treatment options are limited. Intressa Vascular's focus on this area addresses a pressing clinical need, potentially improving patient outcomes significantly.

Competition
Aspect: Somewhat crowded
Summary: The vascular graft market has established players, but specific focus on aortic dissection is less saturated.

While the overall vascular graft market includes major companies like Medtronic and Terumo, the niche focus on aortic dissection may offer a less crowded space. However, competition from established players remains a consideration.

Technical Challenge
Aspect: Moderate
Summary: Developing aortic stents involves moderate technical challenges, including ensuring biocompatibility and durability.

The development of aortic stents requires addressing challenges such as biocompatibility, durability, and precise deployment. While these are significant, they are considered moderate and can be managed with existing technological capabilities.

Patent
Aspect: Applied
Summary: The company has applied for patents related to its multilayer braiding technology.

Intressa Vascular's proprietary multilayer braiding technology is under patent application. If granted, these patents could offer significant protection and a competitive edge in the market.

Financing
Aspect: Medium
Summary: The company has secured significant financing to support clinical studies and product registration.

While current financing supports ongoing clinical studies and regulatory processes, additional funding may be required for full commercialization and scaling operations.

Regulatory
Aspect: Running FIH
Summary: The company is conducting first-in-human (FIH) trials for the Allay Aortic Stent.

Conducting FIH trials is a critical step in the regulatory pathway. Successful completion can pave the way for larger clinical studies and eventual market approval, indicating positive momentum in the regulatory process.

Opportunity Rollup

Odds of Success
3.65
Peak Market Share
5.1
Segment CAGR
5.1%
Market Segment
Aortic and Vascular Graft Devices
Market Sub Segment
Aortic Stent Grafts
Year Post Launch Market Penetration (%)
1 0.26
2 0.76
3 1.78
4 3.57
5 5.10

Key Takeaway

Intressa Vascular addresses a critical clinical need with innovative technology, but faces challenges in competition and funding as it progresses through clinical trials.